Guildford, United Kingdom
Guildford, United Kingdom

Time filter

Source Type

Grant
Agency: GTR | Branch: Innovate UK | Program: | Phase: Collaborative Research & Development | Award Amount: 834.44K | Year: 2013

Blinding diseases are devastating and costly to manage. Currently no treatments exist for inherited forms of blindness, such as Retinitis Pigmentosa (RP), where onset can begin in early childhood. In patients with RP, there are genetic defects in the light-detecting photoreceptor cells of the retina. Without any treatment options available, RP is severely debilitating to a patient population with many potentially productive years of life ahead of them. Stem cell therapies offer a unique potential to treat diseases such as RP. ReNeuron proposes to translate this potential into a treatment for RP using its own particular retinal stem cell technology. Treatment involves injection of the retinal stem cells close to the photoreceptor cells in the back of the eyes. To make this treatment a reality, ReNeuron aims first to demonstrate that its retinal stem cells are safe and effective in preclinical studies supporting a filing for regulatory approval and then to demonstrate safety and efficacy in humans.


Patent
RENEURON Ltd | Date: 2014-02-12

This invention relates to stem cell microparticles and miRNA isolated from these microparticles, their use and production, in particular neural stem cell microparticles and their use in therapy. The stem cell microparticle is typically an exosome or microvesicle and may be derived from a neural stem cell line. The neural stem cell line may be a conditionally-immortalised stem cell line such as CTX0E03 (deposited at the ECACC with Accession No. 04091601). Identified miRNAs include hsa-miR-1246, hsa-miR-4492, hsa-miR-4488 and hsa-miR-4532.


Patent
RENEURON Ltd | Date: 2014-08-14

This invention relates to stem cell microparticles and miRNA isolated from these microparticles, their use and production thereof, in particular neural stem cell microparticles and their use in therapy of a disease or condition involving unwanted or undesirable cell migration. The stem cell microparticle is typically an exosome or microvesicle and may be derived from a neural stem cell line. The neural stem cell line may be a conditionally-immortalised stem cell line such as CTX0E03 (deposited at the ECACC with Accession No. 04091601).


Patent
Reneuron Ltd | Date: 2014-02-12

The invention is based on the finding that microparticles can be produced by conditionally-immortalised cells. The conditionally-immortalised cells may be stem cells. The Examples show the successful harvest of microparticles from conditionally immortalised neural stem cells and CD34+ cells. Conditional immortalisation provides a constant supply of clonal cells that produce microparticles such as exosomes. The conditionally immortalised cells are useful as producer cells for microparticles such as exosomes, which are typically harvested or isolated from the conditionally-immortalised cells.


Patent
RENEURON Ltd | Date: 2013-04-03

This invention relates to stem cell microparticles, their use and production, in particular neural stem cell microparticles and their use in therapy. The stem cell microparticle is typically an exosome or microvesicle and may be derived from a neural stem cell line. The neural stem cell line may be a conditionally-immortalised stem cell line such as CTX0E03 (deposited at the ECACC with Accession No. 04091601).


Patent
RENEURON Ltd | Date: 2014-10-09

This invention relates to stem cell microparticles and miRNA isolated from these microparticles, their use and production thereof, in particular neural stem cell microparticles and their use in therapy of cancer, typically a nestin-positive cancer. The cancer may be glioma, melanoma, breast cancer, pancreatic cancer or prostate cancer. The stem cell microparticle is typically an exosome or microvesicle and may be derived from a neural stem cell line. The neural stem cell line may be a conditionally-immortalised stem cell line such as CTX0E03 (deposited at the ECACC with Accession No. 04091601).


Patent
RENEURON Ltd | Date: 2014-08-04

The present invention uses neural stem cells in the manufacture of a medicament for the treatment of a patient suffering peripheral arterial disease. The invention is particularly suited for treating limb ischemia or Buergers disease.


Grant
Agency: GTR | Branch: Innovate UK | Program: | Phase: Collaborative Research & Development | Award Amount: 2.10M | Year: 2016

ReNeuron is a leading UK regenerative medicine company currently conducting clinical trials with a novel human neural stem cell (hNSC) product for the treatment of stroke and limb ischaemia. These stem cells also produce small parcels of biologic material called exosomes. CTX-derived exosomes have been found to have functional properties in laboratory models of cancer, particularly glioblastomas. It may therefore be feasible to use the exosomes as an alternative class of regenerative medicine that has a long shelf-life and application to a wide range of diseases. In this project, we will tackle how to purify exosomes in large enough quantities cost- effectively at scale and then complete preclinical studies for a clinical trial application in glioblastoma. If successful, our project will benefit patients with the target disease as well as the UK regenerative medicine industry.


Grant
Agency: GTR | Branch: Innovate UK | Program: | Phase: Collaborative Research & Development | Award Amount: 1.26M | Year: 2014

Disability affects approximately 50% of stroke survivors due to permanent loss of brain tissue. ReNeuron is testing the effectiveness of a unique stem cell product, called CTX, in disabled stroke patients. ReNeuron has developed CTX from human brain stem cells, with cell banks established to provide the large quantities needed for clinical use. The safety of CTX has been assessed in stroke-disabled patients in Scotland. Treatment of all patients in this Phase I clinical trial has been completed, with no reports to date of any serious side effects or worsening in disability in the patients. Sustained reductions in neurological impairment and spasticity have also been observed in most patients compared with their stable pre-treatment baseline performance. TSB support is needed to conduct a Phase II study in up to 41 patients with upper limb paralysis at 2-4 months after their strokes. This proposed clinical trial will determine if CTX produces clinically meaningful improvements in the use of the paralysed arm at 6 months post-treatment in a sufficient number of patients treated. Success in this project will represent a significant milestone for ReNeuron and for the wider stroke field.


Grant
Agency: GTR | Branch: Innovate UK | Program: | Phase: Collaborative Research & Development | Award Amount: 393.30K | Year: 2013

This project is led by ReNeuron, a leading UK-based biotechnology business developing stem cell therapies. Critical limb ischaemia, a significant unmet medical need, is the end-stage of peripheral artery disease, resulting in poor blood flow (usually in the lower limb). The leading risk factor for this disease is Type II diabetes which has become an increasing health burden around the world.with rising rates on a global scale. Patients have limited mobility, suffer pain and have non-healing ulcers that eventually progress to gangrene leading to amputations of the limb . Stem cells offer the unique ability to change the course of the underlying disease by promoting the growth of new blood vessels in the affected limb, increasing blood flow. This project aims to take the cell therapy product, CTX-DP, currently in clinical development as a potential treatment for stroke disability, and evaluate its safety in early stage critical limb ischaemia patients in a Phase I UK clinical trial .

Loading ReNeuron Ltd. collaborators
Loading ReNeuron Ltd. collaborators